Socioeconomic differences in preferences and willingness-to-pay for insulin delivery systems in type 1 and type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 11, Issue 9, 2009, Pages 567-573

  Guimarães, Camila ^a,b   Marra, Carlo A ^b   Colley, Lindsey ^b   Gill, Sabrina ^b   Simpson, Scot ^c   Meneilly, Graydon ^b   Queiroz, Regina H C ^a   Lynd, Larry D ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LONG ACTING DRUG; SHORT ACTING DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG USE; EDUCATIONAL STATUS; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCOME; INSULIN DEPENDENT DIABETES MELLITUS; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PRIORITY JOURNAL; SELF REPORT; SOCIOECONOMICS; WEIGHT GAIN;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; AGED; BLOOD GLUCOSE; BRITISH COLUMBIA; CHOICE BEHAVIOR; CONFIDENCE INTERVALS; DIABETES MELLITUS; EDUCATIONAL STATUS; FEMALE; HOMEOSTASIS; HUMANS; INSULIN; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT PREFERENCE; QUESTIONNAIRES; RISK ASSESSMENT; SOCIOECONOMIC FACTORS;

EID: 70349306723     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0034     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention: National diabetes fact sheet. http:==www.cdc.gov=diabetes=pubs=general05.htm (accessed May 30, 2009).
2. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-2012.
3. Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(Suppl 3):S18-S24.
4. Zambanini A, Newson RB, Maisey M, Feher MD: Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46:239-246.
5. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L; The International DAWN Advisory Panel: Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679.
6. Cappelleri JC, Gerber RA, Kourides IA, Gelfand RA: Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. Diabetes Care 2000;23:1799-1803.
7. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV: Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005;28:2543-2545.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
9. Harris SB, Ekoe JM, Zdanowicz Y, Webster-Bogaert S: Gly-cemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). Diabetes Res Clin Pract 2005;70:90-97.
10. Korytkowski M, Niskanen L, Asakura T: FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005;27(Suppl B):S89-S100.
11. International Diabetes Federation: Diabetes atlas: executive summary. www.idf.org=e-atlas (accessed May 30, 2009).
12. Dickinson D, Wilkie P, Harris M: Taking medicines: concordance is not compliance. BMJ 1999;319:787.
13. Vermeire E, Hearnshaw H, Van Royen P, Denekens J: Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharmacol Ther 2001;26: 331-342.
14. Hayes RP, Bowman L, Monahan PO, Marrero DG, McHor-ney CA: Understanding diabetes medications from the perspective of patients with type 2 diabetes: prerequisite to medication concordance. Diabetes Educ 2006;32:404-414.
15. Cefalu WT, Chantal M, Davidson J, Freemantle N, Gough S, Canovatchel W: Patients' perceptions of subcutaneous insulin in the OPTIMIZE study: a multicenter follow-up study. Diabetes Technol Ther 2008;10:25-38.
16. Donaldson C: Valuing the benefits of publicly-provided health care: does 'ability to pay' preclude the use of 'willingness to pay'? Soc Sci Med 1999;49:551-563.
17. Aristides M, Chen J, Schulz M, Williamson E, Clarke S, Grant K: Conjoint analysis of a new chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced colorectal cancer. Pharmacoeconomics 2002;20:775-784.
18. Telser H, Zweifel P: Measuring willingness-to-pay for risk reduction: an application of conjoint analysis. Health Econ 2002;11:129-139.
19. Meister H, Lausberg I, Walger M, von Wedel H: Using conjoint analysis to examine the importance of hearing aid attributes. Ear Hear 2001;22:142-150.
20. Ryan M, Gerard K: Using discrete choice experiments to value health care programmes: current practice and future research reflections. Appl Health Econ Health Policy 2003; 2:55-64.
21. Farrar S, Ryan M, Ross D, Ludbrook A: Using discrete choice modelling in priority setting: an application to clinical service developments. Soc Sci Med 2000;50:63-75.
22. Phillips KA, Maddala T, Johnson FR: Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res 2002;37:1681-1705.
23. Ryan M, McIntosh E, Shackley P: Methodological issues in the application of conjoint analysis in health care. Health Econ 1998;7:373-378.
24. Ryan M, Bate A, Eastmond CJ, Ludbrook A: Use of discrete choice experiments to elicit preferences. Qual Health Care 2001;10(Suppl 1):i55-i60.
25. Kleinman L, McIntosh E, Ryan M, Schmier J, Crawley J, Locke GR 3rd, De Lissovoy G: Willingness to pay for complete symptom relief of gastroesophageal reflux disease. Arch Intern Med 2002;162:1361-1366.
26. Cefalu WT: Optimizing glycemic control. The search for feasible noninvasive insulin delivery systems. Can J Diabetes 2003;27:42-51.
27. Kaplowitz MD, Hoehn JP: Do focus groups and individual interviews reveal the same information for natural resource valuation? Ecol Econ 2001;36:237-247.
28. Sawtooth Software Inc. (CBC=SSI Web) [computer program]. Version 6.4.2. Sequim, WA: Sawtooth Software, 2008.
29. Lynd LD, Sandford AJ, Kelly EM, Paré PD, Bai TR, Fitzgerald JM, Anis AH: Reconcilable differences: a cross-sectional study of the relationship between socioeconomic status and the magnitude of short-acting beta-agonist use in asthma. Chest 2004;126:1161-1168.
30. Marra CA, Lynd LD, Esdaile JM, Kopec J, Anis AH: The impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environment. Rheumatology (Oxford) 2004;43:1390-1397.
31. SAS Statistical Software [computer program]. Version 9.1. Cary, NC: SAS Institute, 2008.
32. Keegan A: Weak pulls the first pulmonary insulin, but uthers are in the works. DOC News 2007;4(12):5.
33. Funnell MM, Anderson RM: MSJAMA: the problem with compliance in diabetes. JAMA 2000;284:1709.
34. Glasgow RE, Anderson RM: In diabetes care, moving from compliance to adherence is not enough. Something entirely different is needed. Diabetes Care 1999;22:2090-2092.
35. Johnson FR, Manjunath R, Mansfield CA, Clayton LJ, Hoerger TJ, Zhang P: High-risk individuals' willingness to pay for diabetes risk-reduction programs. Diabetes Care 2006;29:1351-1356.
36. Bauman AE, Fardy HJ, Harris PG: Getting it right: why bother with patient-centred care? Med J Aust 2003;179: 253-256.